Oncolys BioPharma Inc. (4588.T)
JPY 574.0
(1.59%)
JPY 574.0
(1.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.96 Billion JPY | 27.06% |
| 2022 | 1.54 Billion JPY | -6.68% |
| 2021 | 1.65 Billion JPY | -13.47% |
| 2020 | 1.91 Billion JPY | 12.24% |
| 2019 | 1.7 Billion JPY | 31.48% |
| 2018 | 1.29 Billion JPY | 4.76% |
| 2017 | 1.23 Billion JPY | 18.89% |
| 2016 | 1.03 Billion JPY | -3.1% |
| 2015 | 1.07 Billion JPY | 25.31% |
| 2014 | 856.14 Million JPY | 28.43% |
| 2013 | 666.6 Million JPY | 23.97% |
| 2012 | 537.7 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 378.87 Million JPY | -38.63% |
| 2024 Q2 | 445.88 Million JPY | 17.69% |
| 2023 Q4 | 617.34 Million JPY | 50.55% |
| 2023 FY | 1.96 Billion JPY | 27.06% |
| 2023 Q1 | 328.14 Million JPY | 11.06% |
| 2023 Q2 | 603.44 Million JPY | 83.9% |
| 2023 Q3 | 410.04 Million JPY | -32.05% |
| 2022 FY | 1.54 Billion JPY | -6.68% |
| 2022 Q2 | 386.12 Million JPY | -24.62% |
| 2022 Q1 | 512.23 Million JPY | -1.56% |
| 2022 Q4 | 295.46 Million JPY | -15.38% |
| 2022 Q3 | 349.18 Million JPY | -9.57% |
| 2021 Q3 | 359.87 Million JPY | -9.24% |
| 2021 Q4 | 520.32 Million JPY | 44.58% |
| 2021 Q1 | 376.62 Million JPY | -38.25% |
| 2021 Q2 | 396.52 Million JPY | 5.28% |
| 2021 FY | 1.65 Billion JPY | -13.47% |
| 2020 Q3 | 539.06 Million JPY | 27.35% |
| 2020 Q4 | 609.95 Million JPY | 13.15% |
| 2020 FY | 1.91 Billion JPY | 12.24% |
| 2020 Q2 | 423.28 Million JPY | 25.06% |
| 2020 Q1 | 338.45 Million JPY | -36.67% |
| 2019 FY | 1.7 Billion JPY | 31.48% |
| 2019 Q1 | 371.43 Million JPY | 6.01% |
| 2019 Q3 | 322.59 Million JPY | -31.94% |
| 2019 Q2 | 473.96 Million JPY | 27.6% |
| 2019 Q4 | 534.41 Million JPY | 65.66% |
| 2018 Q3 | 280.24 Million JPY | -21.31% |
| 2018 Q4 | 350.38 Million JPY | 25.03% |
| 2018 Q2 | 356.14 Million JPY | 15.63% |
| 2018 FY | 1.29 Billion JPY | 4.76% |
| 2018 Q1 | 308.01 Million JPY | -30.39% |
| 2017 Q4 | 442.49 Million JPY | 67.67% |
| 2017 FY | 1.23 Billion JPY | 18.89% |
| 2017 Q1 | 250.49 Million JPY | -20.1% |
| 2017 Q2 | 279.06 Million JPY | 11.41% |
| 2017 Q3 | 263.91 Million JPY | -5.43% |
| 2016 Q4 | 313.51 Million JPY | 15.77% |
| 2016 Q3 | 270.82 Million JPY | 11.15% |
| 2016 Q1 | 211.61 Million JPY | -40.25% |
| 2016 FY | 1.03 Billion JPY | -3.1% |
| 2016 Q2 | 243.65 Million JPY | 15.14% |
| 2015 Q1 | 306.33 Million JPY | -5.99% |
| 2015 FY | 1.07 Billion JPY | 25.31% |
| 2015 Q4 | 354.17 Million JPY | 72.41% |
| 2015 Q3 | 205.42 Million JPY | -0.73% |
| 2015 Q2 | 206.92 Million JPY | -32.45% |
| 2014 FY | 856.14 Million JPY | 28.43% |
| 2014 Q2 | 191.55 Million JPY | 12.08% |
| 2014 Q3 | 167.83 Million JPY | -12.38% |
| 2014 Q4 | 325.86 Million JPY | 94.16% |
| 2014 Q1 | 170.89 Million JPY | -33.96% |
| 2013 FY | 666.6 Million JPY | 23.97% |
| 2013 Q4 | 258.78 Million JPY | 0.0% |
| 2012 FY | 537.7 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -52.638% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -239.899% |
| GNI Group Ltd. | 9.32 Billion JPY | 78.969% |
| Linical Co., Ltd. | 2.7 Billion JPY | 27.525% |
| Trans Genic Inc. | 2.15 Billion JPY | 9.225% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -31.481% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 36.159% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -5.58% |
| AnGes, Inc. | 8.9 Billion JPY | 77.976% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -107.892% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 89.783% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -374.731% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -101.01% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 23.64% |
| CanBas Co., Ltd. | 278 Million JPY | -605.249% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -71.75% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -7.846% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -22.249% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 17.416% |
| PeptiDream Inc. | 9.68 Billion JPY | 79.761% |
| Ribomic Inc. | 1.1 Billion JPY | -77.318% |
| SanBio Company Limited | 4.53 Billion JPY | 56.806% |
| Healios K.K. | 3.48 Billion JPY | 43.774% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -69.787% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -46.92% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -39.697% |
| StemRIM | 2.07 Billion JPY | 5.559% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 0.148% |
| FunPep Company Limited | 313.82 Million JPY | -524.748% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -104.652% |
| Stella Pharma Corporation | 963.98 Million JPY | -103.384% |
| TMS Co., Ltd. | 943.25 Million JPY | -107.854% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -79.879% |
| Cuorips Inc. | 598.11 Million JPY | -227.793% |
| K Pharma,Inc. | 543.94 Million JPY | -260.441% |
| Takara Bio Inc. | 23.9 Billion JPY | 91.798% |
| ReproCELL Incorporated | 1.51 Billion JPY | -29.496% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -65.592% |
| StemCell Institute Inc. | 1.16 Billion JPY | -68.708% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -28.793% |
| CellSeed Inc. | 804.93 Million JPY | -143.573% |